Treponema pallidum, 32, 157
Trepopnea, physical findings
diagnostic features, 51
noninfectious mimics, 51
Trimethoprim-sulfamethoxazole (TMP-SMX), 136,
537, 546
Tropical infections, 322
acute abdomen, 329–330
coma and meningoencephalitis, 328–329
dysentery and severe gastrointestinal fluid
losses, 330
fever with eosinophilia, 331
fulminant hepatitis, 330–331
malaria, 324–325
artemesinins, 325–326
quinidine gluconate, 325
severe, treatment of, 333–334
ARDS, 326–328
toxic appearance and fever, 332, 335
Trypticase soy broth, 233
TSS.SeeToxic shock syndrome (TSS)
TSST-1.SeeToxic shock syndrome toxin 1 (TSST-1)
TTE.SeeTransthoracic echocardiography (TTE)
TTP.SeeThrombotic thrombocytopenic purpura
(TTP)
Tuberculoma, 87
Tuberculosis (TB), 155–157
CNS
cavitary pneumonia and, 97
clinical and radiologic diagnosis of, 87
mimic of, 88–89
cutis acuta generalisata, 423
granuloma, 87
infection
anti-TNF therapy and, 380
miliary.SeeMiliary tuberculosis
Tularemia (oculoglandular), 68, 478–479
Tumor, 79
brain, 88–89
damage, 155
emboli, 299
hepatic, 81
pineal, 90
Tumor necrosis factor alpha (TNF-a), 369, 422
Tumor necrosis factor (TNF), 350–351
T1-weighted imaging
of brain, 86
HCC and, 81
T2-weighted imaging, 79, 81
of brain, 86
Typhoidal tularemia, 478
Typhoid fever, 330
UC.SeeUlcerative colitis (UC)
UIP.SeeUsual interstitial pneumonia (UIP)
Ulcerative colitis (UC), 85
Ulceroglandular.SeeGlandular tularemia
Urinary tract infections (UTI), 288, 344, 514.
See alsoUrosepsis
in SOT recipients, 398
Urosepsis, 488
clinical presentation, 289
community-acquired, 288
defined, 288
differential diagnosis of, 289–292
empiric antimicrobial therapy, 292–293
nosocomial, 288–289
Usual interstitial pneumonia (UIP), 99
UTI.SeeUrinary tract infections (UTI)
Uvula, physical findings
diagnostic features, 54
noninfectious mimics, 54VA.SeeVentriculo-atrial (VA)
Vancomycin, 191–192, 400, 507, 527–528, 538, 544
for c. difficile diarrhea, 280–281
dose of, 193
MSSA/MRSA ABE, 211, 213
treats most gram-positive pathogens, 493
Vancomycin-resistant enterococci (VRE), 220, 280,
308, 389, 497, 498
antimicrobial therapy, 499–501
clinical spectrum of, 499
control measures for, in ICU, 119
cost effectiveness, 118–119
epidemiology, 113–115, 499
microbiology of, 498–499
prevention and control of, in ICUs
antimicrobial agents, 117–118
contact precautions, 116
culture surveillance, 116
decontamination of environment, 117
risk factors for acquisition of
in adult ICUs, 113–114
sources of, 113
transmission of, in ICU, 113
type of infection caused by
in adult ICUs, 112
in neonatal ICUs, 113
Vancomycin-resistantS. aureus(VRSA), 308
Vancomycin susceptible enterococci (VSE), 114,
497, 498
VAP.SeeVentilator-associated pneumonia
(VAP)
Varicella zoster virus (VZV), 36, 395
Veridans streptococci, 36, 179, 241
MVP 218
Variola virus, 37
VDRL.SeeVenereal disease research laboratory
(VDRL)
Venereal disease research laboratory
(VDRL), 158
Ventilation/perfusion (V/Q) scan, 92
Ventilator-associated pneumonia (VAP),
488, 514–515
antimicrobial treatment
adequate dosing, 193
aerosolized antibiotics, 193–195
duration of therapy, 196
empiric antibiotic therapy for, 190–191580 Index